These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 27888529)

  • 1. Long-term progression of viral load and serum markers of fibrosis among treated and untreated patients with chronic hepatitis B.
    Li J; Gordon SC; Rupp LB; Zhang T; Trudeau S; Holmberg SD; Moorman AC; Spradling PR; Teshale EH; Boscarino JA; Daida YG; Schmidt MA; Lu M;
    J Gastroenterol Hepatol; 2017 Jun; 32(6):1250-1257. PubMed ID: 27888529
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Serum Biomarkers Indicate Long-term Reduction in Liver Fibrosis in Patients With Sustained Virological Response to Treatment for HCV Infection.
    Lu M; Li J; Zhang T; Rupp LB; Trudeau S; Holmberg SD; Moorman AC; Spradling PR; Teshale EH; Xu F; Boscarino JA; Schmidt MA; Vijayadeva V; Gordon SC;
    Clin Gastroenterol Hepatol; 2016 Jul; 14(7):1044-1055.e3. PubMed ID: 26804385
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Liver fibrosis progression is uncommon in patients with inactive chronic hepatitis B: a prospective cohort study with paired transient elastography examination.
    Wong GL; Chan HL; Yu Z; Chan HY; Tse CH; Wong VW
    J Gastroenterol Hepatol; 2013 Dec; 28(12):1842-8. PubMed ID: 23829381
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Relationship between virological response and FIB-4 index in chronic hepatitis B patients with entecavir therapy.
    Li N; Xu JH; Yu M; Wang S; Si CW; Yu YY
    World J Gastroenterol; 2015 Nov; 21(43):12421-9. PubMed ID: 26604649
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Histological outcome for chronic hepatitis B patients treated with entecavir vs lamivudine-based therapy.
    Wang JL; Du XF; Chen SL; Yu YQ; Wang J; Hu XQ; Shao LY; Chen JZ; Weng XH; Zhang WH
    World J Gastroenterol; 2015 Aug; 21(32):9598-606. PubMed ID: 26327767
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A serum microRNA signature is associated with the immune control of chronic hepatitis B virus infection.
    Brunetto MR; Cavallone D; Oliveri F; Moriconi F; Colombatto P; Coco B; Ciccorossi P; Rastelli C; Romagnoli V; Cherubini B; Teilum MW; Blondal T; Bonino F
    PLoS One; 2014; 9(10):e110782. PubMed ID: 25350115
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Loss of hepatitis B surface antigen in a real-life clinical cohort of patients with chronic hepatitis B virus infection.
    Habersetzer F; Moenne-Loccoz R; Meyer N; Schvoerer E; Simo-Noumbissie P; Dritsas S; Baumert TF; Doffoël M
    Liver Int; 2015 Jan; 35(1):130-9. PubMed ID: 25145784
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Decreasing hepatitis B viral load is associated with a risk of significant liver fibrosis in hepatitis B e antigen positive chronic hepatitis B.
    Xie Q; Hu X; Zhang Y; Jiang X; Li X; Li J
    J Med Virol; 2014 Nov; 86(11):1828-37. PubMed ID: 25145769
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Genetic diversity, viraemic and aminotransferases levels in chronic infected hepatitis B patients from Cameroon.
    Tufon KA; Meriki HD; Anong DN; Mbunkah HA; Nkuo-Akenji T
    BMC Res Notes; 2016 Feb; 9():117. PubMed ID: 26899506
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical course of 161 untreated and tenofovir-treated chronic hepatitis B pregnant patients in a low hepatitis B virus endemic region.
    Samadi Kochaksaraei G; Castillo E; Osman M; Simmonds K; Scott AN; Oshiomogho JI; Lee SS; Myers RP; Martin SR; Coffin CS
    J Viral Hepat; 2016 Jan; 23(1):15-22. PubMed ID: 26192022
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical and histopathological features of chronic hepatitis B virus infected patients with high HBV-DNA viral load and normal alanine aminotransferase level: A multicentre-based study in China.
    Xing YF; Zhou DQ; He JS; Wei CS; Zhong WC; Han ZY; Peng DT; Shao MM; Sham TT; Mok DK; Chan CO; Tong GD
    PLoS One; 2018; 13(9):e0203220. PubMed ID: 30180183
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hepatitis B-associated fibrosis and fibrosis/cirrhosis regression with nucleoside and nucleotide analogs.
    Brown A; Goodman Z
    Expert Rev Gastroenterol Hepatol; 2012 Apr; 6(2):187-98. PubMed ID: 22375524
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Influential factors of prognosis in lamivudine treatment for patients with acute-on-chronic hepatitis B liver failure.
    Sun LJ; Yu JW; Zhao YH; Kang P; Li SC
    J Gastroenterol Hepatol; 2010 Mar; 25(3):583-90. PubMed ID: 19968744
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Viral load speaks little about toll on liver.
    Mahtab MA; Rahman S; Khan M; Kamal M; Mamun AA; Karim MF
    Hepatobiliary Pancreat Dis Int; 2007 Oct; 6(5):483-6. PubMed ID: 17897910
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hepatitis B virus core-related antigen as a surrogate marker for covalently closed circular DNA.
    Wong DK; Seto WK; Cheung KS; Chong CK; Huang FY; Fung J; Lai CL; Yuen MF
    Liver Int; 2017 Jul; 37(7):995-1001. PubMed ID: 27992681
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Predictors of treatment requirement in HBeAg-negative chronic hepatitis B patients with persistently normal alanine aminotransferase and high serum HBV DNA levels.
    Ormeci A; Aydın Y; Sumnu A; Baran B; Soyer OM; Pınarbasi B; Gokturk S; Gulluoglu M; Onel D; Badur S; Akyuz F; Karaca C; Demir K; Besisik F; Kaymakoglu S
    Int J Infect Dis; 2016 Nov; 52():68-73. PubMed ID: 27619844
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Total Hepatitis B Core Antigen Antibody, a Quantitative Non-Invasive Marker of Hepatitis B Virus Induced Liver Disease.
    Yuan Q; Song LW; Cavallone D; Moriconi F; Cherubini B; Colombatto P; Oliveri F; Coco BA; Ricco G; Bonino F; Shih JW; Xia NS; Brunetto MR
    PLoS One; 2015; 10(6):e0130209. PubMed ID: 26115521
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Decline in intrahepatic cccDNA and increase in immune cell reactivity after 12 weeks of antiviral treatment were associated with HBeAg loss.
    Zheng Q; Zhu YY; Chen J; Liu YR; You J; Dong J; Zeng DW; Gao LY; Chen LH; Jiang JJ
    J Viral Hepat; 2014 Dec; 21(12):909-16. PubMed ID: 24888640
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Changes in liver histology as a "surrogate" end point of antiviral therapy for chronic HBV can predict progression to liver complications.
    Hui CK; Leung N; Shek WH; Zhang HY; Luk JM; Poon RT; Lo CM; Fan ST; Lau GK;
    J Clin Gastroenterol; 2008; 42(5):533-8. PubMed ID: 18344885
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of interferon-alpha therapy on liver fibrosis progression in patients with HBeAg-negative chronic hepatitis B.
    Papatheodoridis GV; Petraki K; Cholongitas E; Kanta E; Ketikoglou I; Manesis EK
    J Viral Hepat; 2005 Mar; 12(2):199-206. PubMed ID: 15720536
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.